Richard Alvin Sandberg was the founder of DIANON Systems, Inc., founded in 1983, where the titles held included Chairman, Chief Executive & Financial Officer from 1983 to 1997. Current jobs include Chief Executive Officer at Resolys Bio, Inc. since 2017; Chairman at Precipio Diagnostics LLC; Chairman at Oxford Immunotec Ltd. since 2008; Chairman at Precipio, Inc. since 2021; Independent Director at Quest Diagnostics TB LLC since 2019; and Non-Executive Director at Abcodia Ltd. Former jobs include Chairman & Chief Financial Officer at Lifecodes Corp. from 1997 to 2001; Non-Executive Chairman at OBS Medical Ltd. from 2015 to 2017; Chairman at Concile GmbH; Chairman at SuperNova Diagnostics, Inc.; Chairman-Elect at Jupiter Diagnostics Ltd.; Chief Financial Officer & Director at Matritech, Inc. from 1999 to 2007; Director at Ethan Allen Interiors, Inc. from 2003 to 2009; Director at North American Scientific, Inc. from 2005 to 2009; Director at Cylex, Inc. in 2010; Director at Precipio Diagnostics LLC; Independent Director at Oxford Immunotec Global Ltd. from 2019 to 2021; Director at MZT Holdings, Inc. from 1999 to 2008; Director at Jupiter Diagnostics Holding Co. Ltd.; Chief Financial Officer at Critical Care Diagnostics, Inc.; and Chief Financial Officer at Battery Asset Management LLC from 2004 to 2007. Education includes undergraduate studies at Northwestern University and an MBA from Harvard Business School.
Ilan Danieli
Ilan Danieli is the founder of Precipio Diagnostics LLC, founded in 2011, serving as Chief Executive Officer & Director. Current jobs include Chief Executive Officer & Director at Precipio, Inc. since 2017 and Manager at IDP Holdings LLC. Former jobs include President, Chief Executive Officer & Director at Transgenomic, Inc., Marketing Director at Magnolia Broadband, Inc. from 2000 to 2002, Vice President-Operations at Laurus Capital Management LLC from 2005 to 2007, and Chief Operating Officer at Osiris Corp. Education includes an undergraduate degree from Bar-Ilan University in 1996 and an MBA from the University of Virginia Darden School of Business in 2000.
Jeffrey Cossman
Jeffrey Cossman was the founder of USDS, Inc., founded in 2009, where the title held was Chairman & President from 2013 to 2014. Dr. Cossman is also the founder of Avalon Pharmaceuticals, Inc.,Association for Molecular Pathology,Halcyon Diagnostics, Inc... Dr. Cossman is currently Director at Precipio Diagnostics LLC. Dr. Cossman is also an Independent Director at Precipio, Inc. since 2017. Former positions include Chairman-Pathology Department & Professor at Georgetown University Medical Center, Medical Director & Vice President at Gene Logic, Inc., Secretary & Director at Personalized Medicine Coalition from 2008 to 2014, Senior Investigator Hematopathology at National Cancer Institute, and Chief Science Officer at Critical Path Institute. Education includes a doctorate from the University of Michigan and graduate studies at the University of Michigan Medical School.
David S. Cohen
David S. Cohen is the founder of My Gene Counsel LLC, founded in 2014, and ResCom Energy LLC, founded in 2009, where the title held is President. Mr. Cohen is also the founder of Standard Security Systems,Moneo Technology Solutions LLC,Standard Oil Ventures LLC,Foresite MSP, Inc... Mr. Cohen currently serves as Director at EpiEP, Inc., Phoenix Vintners LLC, Precipio Diagnostics LLC, eBrevia, Inc., iMedX, Inc., Betatronix LLC, The Platt & LaBonia Co LLC, InCytu, Inc., Sirona Medical Technologies, Inc., Emme Controls LLC, CPA Innovations LLC, BloomBoard, Inc., ZoneFlow Reactor Technologies LLC, Omnio Group Ltd., Genixo Construction LLC, and Standard Oil of Connecticut, Inc. where the title is Chief Operating Officer. Mr. Cohen is an Independent Director at Precipio, Inc. since 2017. Former positions include Director at SOMS Technologies LLC and Director at gomembers, Inc. Education includes an MBA degree from Harvard Business School conferred in 1984 and an undergraduate degree from Harvard College conferred in 1980.
Kathy D. LaPorte
Kathy D. LaPorte was the founder of New Leaf Venture Partners LLC, founded in 2005, holding the title of Partner. Ms. LaPorte is also the founder of HealthTech Capital Co. Ms. LaPorte is currently Director at Aesthetic Sciences Corp. and Precipio Diagnostics LLC. Ms. LaPorte is Independent Director at Bolt Biotherapeutics, Inc. since 2020, Precipio, Inc. since 2018, CERo Therapeutics Holdings, Inc. since 2021, and Q32 Bio, Inc. since 2024. Ms. LaPorte is Director at Elysium Therapeutics, Inc. since 2016, Q32 Bio Operations, Inc. since 2021, and D2G Oncology, Inc. since 2020. Former positions include Chief Executive Officer at Nodality, Inc. from 2015 to 2016; Director at Cytyc Prenatal Products Corp., Onyx Pharmaceuticals, Inc., eHealth, Inc., Cellgate, Inc., Prometheus Laboratories, Inc., Pearl Therapeutics, Inc., and Western Association of Venture Capitalists (President). Director at ISTA Pharmaceuticals, Inc. from 2002 to 2011; VNUS Medical Technologies, Inc. from 1997 to 2008; Transcept Pharmaceuticals, Inc. (Old) in 2009; Affymax, Inc. (Independent Director) from 2011 to 2013; eHealthInsurance Services, Inc. from 2000 to 2007; California Institute for Regenerative Medicine from 2014 to 2017; Transcept Pharma, Inc. (Independent Director) from 2011 to 2012; Phoenix Biotech Acquisition Corp. (Independent Director) from 2021 to 2024; 89bio, Inc. (Independent Director) from 2021 to 2025; New Leaf Venture Partners LLC (Partner) from 2005 to 2011; Sprout Group (General Partner) from 1993 to 2004; Credit Suisse Securities (USA) LLC (General Partner) in 2005; Asset Management Co. (Principal) from 1987 to 1992; and Analyst at First Boston Corp. Education included undergraduate degree from Yale University in 1983 and MBA from Stanford Graduate School of Business in 1987.
Richard Alvin Sandberg
Richard Alvin Sandberg was the founder of DIANON Systems, Inc., founded in 1983, where the titles held included Chairman, Chief Executive & Financial Officer from 1983 to 1997. Current jobs include Chief Executive Officer at Resolys Bio, Inc. since 2017; Chairman at Precipio Diagnostics LLC; Chairman at Oxford Immunotec Ltd. since 2008; Chairman at Precipio, Inc. since 2021; Independent Director at Quest Diagnostics TB LLC since 2019; and Non-Executive Director at Abcodia Ltd. Former jobs include Chairman & Chief Financial Officer at Lifecodes Corp. from 1997 to 2001; Non-Executive Chairman at OBS Medical Ltd. from 2015 to 2017; Chairman at Concile GmbH; Chairman at SuperNova Diagnostics, Inc.; Chairman-Elect at Jupiter Diagnostics Ltd.; Chief Financial Officer & Director at Matritech, Inc. from 1999 to 2007; Director at Ethan Allen Interiors, Inc. from 2003 to 2009; Director at North American Scientific, Inc. from 2005 to 2009; Director at Cylex, Inc. in 2010; Director at Precipio Diagnostics LLC; Independent Director at Oxford Immunotec Global Ltd. from 2019 to 2021; Director at MZT Holdings, Inc. from 1999 to 2008; Director at Jupiter Diagnostics Holding Co. Ltd.; Chief Financial Officer at Critical Care Diagnostics, Inc.; and Chief Financial Officer at Battery Asset Management LLC from 2004 to 2007. Education includes undergraduate studies at Northwestern University and an MBA from Harvard Business School.
Ronald Asbury Andrews
Ronald Asbury Andrews was the founder of Bethesda Group Fund, founded in 2015, serving as Principal. Current jobs include Executive Chairman at Dxcover Ltd. since 2023; Director at Oxford Immunotec Ltd. since 2015; Director at Mission Hospital Foundation; Director at Quest Diagnostics TB LLC since 2015; Independent Director at Cellmax, Inc. since 2023; Independent Director at Precipio, Inc. since 2021; Independent Director at Plus Therapeutics, Inc. starting 2026; Director at Precipio Diagnostics LLC; Trustee at Wofford College; and Member-Supervisory Board at Agendia, Inc. since 2023. Former jobs include Chief Executive Officer-GE Molecular Diagnostics at Clarient, Inc. from 2010 to 2012; Chief Executive Officer-Clarient Business Unit at GE Healthcare, Inc. in 2012; Chief Executive Officer & Director at Insight Molecular Diagnostics, Inc. in 2022; Chief Executive Officer & Director at Twinstrand Biosciences, Inc. from 2023 to 2024; Executive Chairman at SimBioSys, Inc. from 2022 to 2024; Independent Non-Executive Director at Oxford Immunotec Global Ltd. from 2015 to 2021; Director at Cardiac Science Corp. from 2009 to 2010; Independent Director at Orion Health Group Ltd. and Orion Health Ltd. from 2016 to 2018; Director at Insight Genetics, Inc. from 2015 to 2019; Vice President at Immucor, Inc.; Vice President-Marketing at Roche Diagnostics Corp.; President-Genetic Sciences Division at Thermo Fisher Scientific, Inc. from 2013 to 2014; Senior Vice President-Global Marketing at Roche Molecular Systems, Inc. from 2000 to 2004; Senior Marketing Manager-Business Unit Operations at Abbott Diagnostics, Inc.; President-Medical Sciences at Life Technologies Corp. from 2012 to 2013; Member-Governors Board at CancerLinQ LLC from 2016 to 2023; and Managing Partner at Ph Blueprint. Education includes an undergraduate degree from Wofford College, conferred in 1981.
Christina Valauri
Christina Valauri is the founder of Sagestone Advisory, LLC, founded in 2016, serving as Chief Executive Officer since 2017. Current jobs include Independent Director at Precipio, Inc. starting in 2024 and Independent Director at Valion Bio, Inc. starting in 2024. Former jobs include Director-Equity Research at BroadPoint Securities Group, Inc. from 2001 to 2008; Managing Director & Global Director of Research at Cantor Fitzgerald Securities from 2013 to 2015; Global Director-Research at Cantor Fitzgerald & Co.; Associate Director-Equity Research at ING Barings LLC from 2000 to 2001; Director-Equity Research at Gleacher & Co., Inc.; Director-Equity Research at Credit Lyonnais (USA), Inc. in 2000; and Senior Manager at Natixis Securities Americas LLC from 2012 to 2013. Education includes an undergraduate degree from The Reed Institute in 1978 and an MBA from Cornell University.
提供，免责声明：天汇财经、Factset及其他信息供应商努力确保所提供信息的准确性和可靠性，但对于其正确性或可靠性则不予担保，且对于因不正确或疏漏所造成的任何损失或损坏概不负责(无论是有关民事过失、合同或其他方面)。